Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 9:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 45 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: HAART regimen Clear all

Conditions: HIV Infection
Interventions: LPV/RTV + 2NRTIs; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 13
States / cities: Phoenix, Arizona • Altamonte Springs, Florida • Fort Lauderdale, Florida + 10 more

Conditions: HIV
Interventions: Raltegravir; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: HIV Infections
Interventions: Indinavir sulfate, Abacavir sulfate, Nelfinavir mesylate, Efavirenz, Nevirapine, Lamivudine, Stavudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 1,710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 17
States / cities: San Francisco, California • Denver, Colorado • New Haven, Connecticut + 13 more

Conditions: HIV Infection
Interventions: Lopinavir/Ritonavir; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: North Chicago, Illinois

Conditions: HIV Infections
Interventions: Efavirenz + 2 NRTIs, Lopinavir/Ritonavir + 2 NRTIs, Therapeutic Drug Monitoring; Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 23 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 13
States / cities: Alhambra, California • Long Beach, California • Los Angeles, California + 9 more

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: CAB Oral Tablets, CAB LA, ABC/3TC Oral tablets, RPV Oral Tablets, HAART, RPV; Drug · Other
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 15
States / cities: Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 12 more

Conditions: HIV Disease
Interventions: HAART regimen, 3TC or FTC monotherapy; Drug
Lead sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Network
Eligibility: 8 Years to 24 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 10
States / cities: San Francisco, California • Washington D.C., District of Columbia • Jacksonville, Florida + 7 more

Conditions: HIV, HIV Infections
Interventions: ZFN modified T cells, Structured Treatment Interruption; Biological · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: The Bronx, New York • Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: KP-1461; Drug
Lead sponsor: Koronis Pharmaceuticals.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 9
States / cities: Bradenton, Florida • Miami, Florida • West Palm Beach, Florida + 6 more

Conditions: HIV Infections, AIDS
Interventions: Tenofovir, Hydroxyurea; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections, Hepatitis C
Interventions: Alcohol, Alcohol placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 20 Years to 60 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infection
Interventions: Maraviroc; Drug
Lead sponsor: Southern California Institute for Research and Education; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Long Beach, California

Conditions: AIDS-Related Hodgkin Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, HIV Infection, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma
Interventions: Gene-Modified HIV-Protected Hematopoietic Stem Cells, Laboratory Biomarker Analysis, Transplant Conditioning; Biological · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 66 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV Infections
Interventions: Atazanavir, Lopinavir/Ritonavir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 38
States / cities: Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 30 more

Conditions: HIV Infections
Interventions: HIV-1 Immunogen; Biological
Lead sponsor: Agouron Pharmaceuticals; Industry
Eligibility: 13 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Diego, California

Conditions: HIV Infections
Interventions: Atazanavir+ritonavir, Lopinavir+ritonavir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 52
States / cities: Hobson City, Alabama • Montgomery, Alabama • Phoenix, Arizona + 49 more

Conditions: Acquired Immunodeficiency Syndrome, Human Immunodeficiency Virus Type
Interventions: Not listed
Lead sponsor: Olayemi Osiyemi MD; Other
Eligibility: 18 Years and older
Enrollment: 445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: West Palm Beach, Florida

Conditions: HIV Infections
Interventions: Abacavir sulfate, Emtricitabine, Lamivudine, Lopinavir/ritonavir, Saquinavir, Tenofovir disoproxil fumarate, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 4 Years to 21 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 4
States / cities: Chicago, Illinois • New York, New York • Stony Brook, New York + 1 more

Conditions: HIV Infections
Interventions: Ritonavir, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 3
States / cities: Aurora, Colorado • Chicago, Illinois • Cleveland, Ohio

Conditions: HIV Infection
Interventions: Highly active antiretroviral therapy (HAART); Drug
Lead sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 1,653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 26
States / cities: Alhambra, California • Los Angeles, California • San Diego, California + 20 more

Search by objective public record fields.

Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects

Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen

A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)

Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral Therapy

Anti-HIV Drug Regimens With or Without Protease Inhibitors and Drug Level Monitoring in HIV Infected Adolescents

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy

Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV

Study of KP-1461 for the Treatment of HIV Positive Patients Who Have Failed Multiple HAART Regimens

Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral Suppression

Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection

HIV Fat Redistribution and the Evaluation of Brown Fat

Adding Maraviroc to the HAART Regimen of Well Controlled HIV-infected Patients

Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)

Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen

Adherence & Health Outcome Differences Amongst HIV Infected Patients Prescribed HAART

A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy

The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients

IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women